This study aimed to explore the change of immune cell landscape after ofatumumab treatment in patients with relapsing-remitting multiple sclerosis (RRMS).
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: